The American Journal of Medicine
Volume 122, Issue 2 , Pages 162.e1-162.e9, February 2009

“Dose-dependent” Impact of Recurrent Cardiac Events on Mortality in Patients with Heart Failure

  • Douglas S. Lee, MD, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ont, Canada
    • Division of Cardiology of University Health Network and Mt. Sinai Hospital, Toronto, Ont, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Douglas S. Lee, MD, PhD, Institute for Clinical Evaluative Sciences, Rm G-106, 2075 Bayview Ave., Toronto, ON, Canada
  • ,
  • Peter C. Austin, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ont, Canada
    • Department of Health Policy, Management and Evaluation, Toronto, Ont, Canada
  • ,
  • Thérèse A. Stukel, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ont, Canada
    • Department of Health Policy, Management and Evaluation, Toronto, Ont, Canada
  • ,
  • David A. Alter, MD, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ont, Canada
    • Department of Health Policy, Management and Evaluation, Toronto, Ont, Canada
    • Division of Cardiology of St. Michael's Hospital, Toronto, Ont, Canada
  • ,
  • Alice Chong, BSc

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ont, Canada
  • ,
  • John D. Parker, MD

      Affiliations

    • Division of Cardiology of University Health Network and Mt. Sinai Hospital, Toronto, Ont, Canada
  • ,
  • Jack V. Tu, MD, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ont, Canada
    • Department of Health Policy, Management and Evaluation, Toronto, Ont, Canada
    • Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Ont, Canada

published online 19 December 2008.

Abstract 

Background

The mortality impact of recurrent cardiac hospitalizations has not been delineated in community-based heart failure patients. We determined if a “dose-dependent” relationship exists between heart failure events and death, accounting for temporal changes in age, comorbidities, and disease severity.

Methods

Among heart failure patients in the Enhanced Feedback For Effective Cardiac Treatment Study with onset between April 1999 and March 2001, we compared long-term survival (until March 2006) in those with recurrent heart failure or cardiovascular events, relative to those free of such events.

Results

In 9138 patients, 28,442 person-years of follow-up were examined (mean age: 75.3 years, 49.6% male). Recurrent heart failure events occurred 1, 2, 3, and ≥4 times in 2352 (25.7%), 1020 (11.2%), 505 (5.5%), and 596 (6.5%) patients, respectively. Cardiovascular readmissions occurred 1, 2, 3, and ≥4 times in 2522 (27.6%), 1509 (16.5%), 975 (10.7%), and 1672 (18.3%) patients, respectively. Compared with those without recurrent heart failure events, the adjusted relative mortality rates for 1, 2, 3, and ≥4 heart failure events were 2.41 (95% confidence interval [CI], 2.24-2.60), 3.00 (95% CI 2.72-3.32), 4.00 (95% CI, 3.51-4.56), and 5.16 (95% CI, 4.55-5.85), respectively. Compared with those without cardiovascular events, the adjusted relative mortality rates for 1, 2, 3, and ≥4 cardiovascular events were 3.33 (95% CI, 3.05-3.63), 4.61 (95% CI, 4.16-5.10), 6.29 (95% CI, 5.59-7.07), and 8.95 (95% CI, 8.05-9.95), respectively.

Conclusions

The risk of death increases progressively and independently with each heart failure or cardiovascular event. The number of prior events predicts mortality and should be ascertained in patients with heart failure.

Keywords: heart failure, hospitalizations, mortality, outcomes research, prognosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding: This research was supported by a Canadian Institutes of Health Research (CIHR) grant and a CIHR Team Grant in Cardiovascular Outcomes Research, a clinician-scientist (DSL) and new investigator award (PCA) from the CIHR, career investigator awards from the Heart and Stroke Foundation of Ontario (JVT, DAA), and a Canada Research Chair in health services research (JVT).

 Conflict of Interest: The authors have no conflict of interest to disclose.

 Authorship: All co-authors had access to the data and contributed to the manuscript.

PII: S0002-9343(08)00958-3

doi:10.1016/j.amjmed.2008.08.026

The American Journal of Medicine
Volume 122, Issue 2 , Pages 162.e1-162.e9, February 2009